340B Oncology Practices: Why the Program Matters for Financing
The federal 340B drug pricing program has quietly reshaped community cancer care, and understanding how 340B oncology practices differ from independent ones can help owners make better decisions about growth, partnerships and a possible sale. The program allows certain eligible hospitals and clinics to purchase many outpatient drugs at discounted prices, and oncology drugs are among the most expensive outpatient medications.
Because independent physician practices generally are not eligible, the program can create a significant economic gap between hospital-owned and physician-owned oncology. This article explains why that matters for financing and transactions. It is general education only. Program rules are complex and subject to change, eligibility depends on specific facts, and nothing here is legal, tax, billing or compliance advice. Healthcare counsel and qualified compliance professionals should review any 340B question.
A Brief Overview of the Program
Under the program, drug manufacturers that participate in Medicaid agree to sell covered outpatient drugs at reduced prices to eligible organizations, often called covered entities. These typically include certain nonprofit and public hospitals that serve large low-income populations, along with some federally supported clinics.
Covered entities may be reimbursed by payers at rates that do not reflect the discount, and the difference can be substantial for high-cost drugs. Supporters say the margin helps fund care for underserved patients. Critics argue it encourages hospitals to expand into lucrative service lines. Both views shape the policy debate.
Why Hospitals Acquire Oncology Practices
When an eligible hospital acquires an independent oncology practice and integrates it as a hospital outpatient location, drugs administered there may, depending on program rules and registration, become eligible for discounted pricing. For a practice that administers a large volume of expensive infusions, that change can significantly alter the economics.
This is one reason hospitals may be willing to offer sellers terms that an individual physician buyer or private group cannot match. Owners weighing their options may find our article on how to sell an oncology practice helpful.
How 340B Oncology Practices Affect Valuation
The value of an oncology practice can look very different depending on who is buying. A hospital with program access may see revenue potential that does not exist for an independent owner. A physician buyer, by contrast, must rely on the practice’s own historical cash flow and the drug margins available to a physician-owned office.
Lenders financing a physician acquisition will generally underwrite to the practice’s demonstrated earnings, not to economics only a hospital can capture. Our article on oncology practice valuation explains the factors that drive value for independent buyers.
Competitive Pressure on Independent Practices
Independent practices may compete for patients and referrals with hospital-owned programs that benefit from drug discounts. That can affect:
- Recruiting, as hospital programs may offer different compensation packages
- Referral patterns, if hospitals encourage referrals to owned practices
- Payer negotiations, which may differ for hospital outpatient settings
- Long-term planning for practices deciding whether to remain independent
At the same time, some commercial insurers encourage infusions in lower-cost physician office settings, which can support independent practices.
Policy Uncertainty and Recent Proposals
The program is the subject of ongoing legislative, regulatory and legal activity. Medicare has proposed changes affecting how it pays hospitals for drugs acquired under the program, and other proposals have addressed contract pharmacy arrangements, transparency and eligibility. Proposals may change before being finalized, and some may not take effect at all.
For independent practices, these changes may matter indirectly. If hospital economics shift, acquisition interest and pricing for oncology practices may shift too. Owners should monitor developments with counsel and advisors rather than assume current conditions will continue.
What This Means for Financing
For physician-owned practices seeking financing, 340B dynamics may come up in several ways:
- Acquisitions: a physician buyer may compete with a hospital for the same practice, which can affect price and structure
- Partner buyouts: remaining partners may weigh an internal buyout against a hospital offer; our article on the oncology partner buyout covers that decision
- Underwriting: lenders will focus on the practice’s own payer mix and drug margins rather than program economics it cannot access
- Growth plans: expansion decisions may account for nearby hospital-based competitors
Payer mix remains central to underwriting. Our article on oncology practice payer mix explains how lenders view Medicare-heavy revenue.
How Independent Practices Respond
Many independent groups focus on what they can control. Some strengthen purchasing through group arrangements, add services such as in-office dispensing or imaging, or open satellite clinics closer to patients. Others join physician-led networks for scale while keeping clinical autonomy. Each strategy carries its own costs and regulatory considerations, and each should be evaluated with counsel and advisors. Financing can support these strategies when they are grounded in the practice’s own cash flow.
Questions Owners May Want to Ask
- How would our practice’s value differ for a hospital buyer versus a physician buyer?
- What would change for patients and staff under hospital ownership?
- How might policy changes affect hospital interest in our market?
- Can our practice’s cash flow support an internal succession plan?
Our advisory and consulting services can help owners think through succession and exit options.
Final Thoughts
The 340B program is a major force behind hospital acquisitions in oncology, and it shapes how 340B oncology practices compete with independent groups. For physician owners and buyers, the key is understanding which economics the practice itself can rely on, planning for policy uncertainty, and structuring financing around demonstrated cash flow.
US Medical Funding helps independent oncologists finance acquisitions, buyouts and growth. Learn more about our oncology practice acquisition financing and our full range of oncology practice financing options.
